Geode Capital Management LLC Boosts Holdings in Apogee Therapeutics Inc. $APGE

Posted by George Bondi on Jun 8th, 2026

Geode Capital Management LLC grew its stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 18.7% in the fourth quarter, Holdings Channel reports. The firm owned 1,059,085 shares of the company’s stock after acquiring an additional 166,882 shares during the period. Geode Capital Management LLC’s holdings in Apogee Therapeutics were worth $79,957,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd boosted its stake in shares of Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares during the period. Comerica Bank boosted its stake in shares of Apogee Therapeutics by 1.0% during the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock valued at $2,708,000 after purchasing an additional 338 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after purchasing an additional 694 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Apogee Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,935 shares of the company’s stock valued at $674,000 after purchasing an additional 853 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Apogee Therapeutics by 49.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,665 shares of the company’s stock valued at $201,000 after purchasing an additional 882 shares during the period. 79.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on APGE. Canaccord Genuity Group boosted their target price on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Citigroup boosted their target price on shares of Apogee Therapeutics from $95.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. The Goldman Sachs Group set a $89.00 price objective on Apogee Therapeutics in a report on Thursday, May 28th. Guggenheim lifted their price objective on Apogee Therapeutics from $130.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Mizuho lifted their price objective on Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $113.63.

Check Out Our Latest Analysis on Apogee Therapeutics

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total value of $432,905.00. Following the completion of the transaction, the insider directly owned 205,648 shares in the company, valued at approximately $16,186,554.08. The trade was a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the completion of the transaction, the chief executive officer owned 1,132,987 shares of the company’s stock, valued at $93,562,066.46. This represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 76,500 shares of company stock valued at $6,151,295 over the last quarter. 24.30% of the stock is currently owned by corporate insiders.

Apogee Therapeutics Stock Performance

Shares of Apogee Therapeutics stock opened at $86.92 on Monday. The company has a market capitalization of $5.38 billion, a PE ratio of -20.07 and a beta of 0.62. The company has a 50-day simple moving average of $83.96 and a two-hundred day simple moving average of $76.67. Apogee Therapeutics Inc. has a one year low of $34.34 and a one year high of $95.32.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.01. On average, equities analysts predict that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Apogee Therapeutics Company Profile

(Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.